CraniUS Therapeutics LLC, a privately held neurotechnology company, today announced the appointment of Oray B. Boston Jr. to its Board of Directors. Mr. Boston brings more than 35 years of global ...

The startup, which counts recent Johns Hopkins university alums among its senior-most employees, will put the funds toward developing prototypes of its flagship device for delivering medicine directly ...

The Johns Hopkins spinout's implant injects drugs directly into the brain, bypassing a barrier that blocks 95% of medications ...

The MarketWatch News Department was not involved in the creation of this content. Enabling Direct Therapeutic Access Beyond the Blood-Brain Barrier BALTIMORE, Jan. 28, 2026 /PRNewswire/ -- CraniUS ...

BALTIMORE, May 29, 2025 /PRNewswire/ -- CraniUS Therapeutics, a cutting-edge medical device company advancing intracranial drug delivery, is proud to announce it has been voted the "2025 Emerging Life ...

CraniUS becomes the first company with a smart, refillable, and fully embedded medical device that effectively bypasses the blood-brain barrier and achieves long-term, convection-enhanced medicine ...

Dr. Henry Brem joins CraniUS Board of Directors in further enhancing its mission to facilitate chronic and direct medicine delivery for treating brain disease. BALTIMORE, Nov. 15, 2022 /PRNewswire/ -- ...

The latest patent filing from Cranius LLC describes a reservoir for its implanted drug delivery devices which is shaped and formed to empty and fill reliably without any concern for neighboring organ ...

Global Healthcare Executive Brings Extensive Commercial and Product Launch Experience BALTIMORE, Feb. 18, 2026 /PRNewswire/ -- CraniUS Therapeutics LLC, a privately held neurotechnology company, today ...

BALTIMORE, Jan. 28, 2026 /PRNewswire/ -- CraniUS Therapeutics LLC, a privately held neurotechnology company, today announced it has raised $20 million in Series B financing to accelerate development ...